Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial

Angelo Di Leo, Stephen R.D. Johnston, Keun Seok Lee et al. · The Lancet Oncology · 2017

Cited by 381 works. doi:10.1016/s1470-2045(17)30688-5

Authors

References